Nektar Therapeutics (NKTR) Change in Account Payables (2010 - 2026)

Nektar Therapeutics' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$934000.0 for Q1 2026.

• In Q1 2026, Change in Account Payables fell 114.57% year-over-year to -$934000.0; the TTM figure through Mar 2026 stood at -$8.0 million (down 179.17% YoY), while the FY2025 annual figure was -$625000.0, down 123.43% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$934000.0, up from -$4.8 million in the prior quarter.
• The five-year high for Change in Account Payables was $7.3 million in Q4 2022, with the low at -$8.9 million in Q1 2023.
• The 5-year median for Change in Account Payables is -$165000.0 (2022), against an average of $78117.6.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables plunged 552.73% in 2023, then soared 748.79% in 2025.
• Nektar Therapeutics' Change in Account Payables stood at $7.3 million in 2022, then dropped by 11.57% to $6.4 million in 2023, then tumbled by 42.72% to $3.7 million in 2024, then sank by 229.86% to -$4.8 million in 2025, then soared by 80.51% to -$934000.0 in 2026.
• Business Quant data shows NKTR's Change in Account Payables at -$934000.0 in Q1 2026, -$4.8 million in Q4 2025, and $1.3 million in Q3 2025.